Boxer Capital Management, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0002018299
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2025 · 20 positions · Total reported value $198.66M · Top-10 concentration 91.4% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 24.2% · 12 new · 1 cut · 3 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +34.8% · vs SPY +19.9% · Prev Value $761.65M — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2025 13F filing, Boxer Capital Management, LLC disclosed 20 equity positions with a combined reported value of $198.66M. The filing implies a focused portfolio: its ten largest positions account for 91.4% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2025 were TNGX ($50.03M), RVMD ($29.17M), REPL ($20.54M). By sector, the heaviest allocations are Health Care 84.3%, Other 15.7%. Versus the prior quarter, allocation shifted toward Health Care (+22.6pp) and away from Other (-22.6pp).
Versus the prior quarter, Boxer Capital Management, LLC opened 12 new positions, trimmed 1 and fully exited 3, a turnover rate of 24.2% of positions. The portfolio's overlap with the prior quarter was 33% of names.
The largest new positions opened in Q2 2025 were ITOS ($8.23M), URGN ($7.88M), CBIO ($7.32M).
Of the 3 positions fully exited versus the prior quarter, the largest were NUVL ($31.91M), RNAM ($25.53M), ANAB ($24.17M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2025)
- ITOS ITEOS THERAPEUTICS INC · $8.23M
- URGN UROGEN PHARMA LTD · $7.88M
- CBIO CRESCENT BIOPHARMA INC. · $7.32M
- PTGX PROTAGONIST THERAPEUTICS INC · $3.32M
- NKTR NEKTAR THERAPEUTICS · $3.23M
- CDTX CIDARA THERAPEUTICS INC · $2.68M
- KALV KALVISTA PHARMACEUTICALS INC · $1.06M
- SRPT SAREPTA THERAPEUTICS INC · $427.50K
Fully Exited (vs previous quarter)
- NUVL NUVALENT INC · prev qtr: $31.91M
- RNAM AVIDITY BIOSCIENCES INC · prev qtr: $25.53M
- ANAB ANAPTYSBIO INC · prev qtr: $24.17M
- XENE XENON PHARMACEUTICALS INC · prev qtr: $20.13M
- APLS APELLIS PHARMACEUTICALS INC · prev qtr: $15.59M
- CMRX CHIMERIX INC · prev qtr: $15.40M
- ELVN ENLIVEN THERAPEUTICS INC · prev qtr: $13.21M
- ORIC ORIC PHARMACEUTICALS INC · prev qtr: $9.67M · history
Insider Transactions (Form 4)
Latest Boxer Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Boxer Capital Management, LLC is an SEC-registered 13F filer based in San Diego, CA, United States. As of Q2 2026 it reported 63 US equity positions with a combined value of $1.33B. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).
Firm Snapshot
- Headquarters: SAN DIEGO, CA, United States
- SEC registration: 801-130351 (status: Approved), registered 2024-05-24
- Regulatory AUM (Form ADV): $578.22M as of 2026-05-11
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 2 hedge funds
- Website: boxercap.com
Portfolio Structure
- 63 positions · $1.33B reported value (Q2 2026)
- Top 10 holdings = 65.1% of reported value
- Largest position: TNGX (TANGO THERAPEUTICS INC COM) at 25.6%
- Average position size: $21.08M
Sector Tilt
- Health Care 98.5%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 12 new, 17 added, 1 reduced, 3 exited
- 33 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
9.77M | $50.03M | 25.18% | Reduce | |
| 2 |
|
792.98K | $29.17M | 14.69% | Reduce | |
| 3 |
|
2.21M | $20.54M | 10.34% | Add | |
| 4 |
|
365.00K | $19.20M | 9.66% | Reduce | |
| 5 |
|
432.01K | $18.85M | 9.49% | Add | |
| 6 |
|
899.50K | $12.54M | 6.31% | Add | |
| 7 |
|
825.00K | $8.23M | 4.14% | New | |
| 8 |
|
575.00K | $7.88M | 3.96% | New | |
| 9 |
|
1.23M | $7.85M | 3.95% | Reduce | |
| 10 |
|
453.69K | $7.32M | 3.69% | New | |
| 11 |
|
60.00K | $3.32M | 1.67% | New | |
| 12 |
|
125.00K | $3.23M | 1.63% | New | |
| 13 |
|
750.00K | $2.80M | 1.41% | Reduce | |
| 14 |
|
55.00K | $2.68M | 1.35% | New | |
| 15 |
|
175.00K | $1.99M | 1.00% | Reduce | |
| 16 |
|
70.70K | $1.47M | 0.74% | Reduce | |
| 17 |
|
93.40K | $1.06M | 0.53% | New | |
| 18 |
|
25.00K | $427.50K | 0.21% | New | |
| 19 |
|
266.67K | $71.97K | 0.04% | Hold | |
| 20 |
|
66.67K | $1.21K | 0.00% | Hold | |
FAQ
What did Boxer Capital Management, LLC buy in 2025-Q2?
In its 2025-Q2 13F filing, Boxer Capital Management, LLC reported 20 equity positions worth $198.66M in aggregate; its largest disclosed positions were TNGX ($50.03M), RVMD ($29.17M), REPL ($20.54M).
How large is Boxer Capital Management, LLC's portfolio?
Boxer Capital Management, LLC reported $198.66M of long equity holdings across 20 positions as of 2025-Q2. Top-10 holdings account for 91.4% of reported value.
What is Boxer Capital Management, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.